Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Intensive multifactorial intervention improves modelled coronary heart disease risk in screen-detected Type 2 diabetes mellitus: a cluster randomized controlled trial.

Webb DR, Khunti K, Gray LJ, Srinivasan BT, Farooqi A, Wareham N, Griffin SC, Davies MJ; ADDITION-Leicester study group..

Diabet Med. 2012 Apr;29(4):531-40. doi: 10.1111/j.1464-5491.2011.03441.x.

PMID:
21913966
2.

Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial.

Ladhani NN, Majumdar SR, Johnson JA, Tsuyuki RT, Lewanczuk RZ, Spooner R, Simpson SH.

Diabet Med. 2012 Nov;29(11):1433-9. doi: 10.1111/j.1464-5491.2012.03673.x.

PMID:
22486226
3.
4.
5.

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial.

Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T.

Lancet. 2011 Jul 9;378(9786):156-67. doi: 10.1016/S0140-6736(11)60698-3. Epub 2011 Jun 24. Erratum in: Lancet. 2012 Mar 3;379(9818):804.

7.

Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.

Webb DR, Khunti K, Srinivasan B, Gray LJ, Taub N, Campbell S, Barnett J, Henson J, Hiles S, Farooqi A, Griffin SJ, Wareham NJ, Davies MJ.

Trials. 2010 Feb 19;11:16. doi: 10.1186/1745-6215-11-16.

8.

Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.

Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group..

Diabetes Obes Metab. 2009 Jun;11(6):623-31. doi: 10.1111/j.1463-1326.2009.01060.x.

PMID:
19515182
9.

Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).

Gudbjörnsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, Nilsson PM; Swedish National Diabetes Register (NDR)..

Diabet Med. 2009 Jan;26(1):53-60. doi: 10.1111/j.1464-5491.2008.02633.x.

PMID:
19125761
10.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
11.

Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study.

Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, Borch-Johnsen K, Wareham NJ, Lauritzen T.

Diabetologia. 2008 Jul;51(7):1127-34. doi: 10.1007/s00125-008-1013-0. Epub 2008 Apr 29.

12.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
13.
14.

Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial.

Black JA, Sharp SJ, Wareham NJ, Sandbaek A, Rutten GE, Lauritzen T, Khunti K, Davies MJ, Borch-Johnsen K, Griffin SJ, Simmons RK.

Diabet Med. 2014 Jun;31(6):647-56. doi: 10.1111/dme.12410. Epub 2014 Apr 1.

15.

Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.

Launer LJ, Miller ME, Williamson JD, Lazar RM, Gerstein HC, Murray AM, Sullivan M, Horowitz KR, Ding J, Marcovina S, Lovato LC, Lovato J, Margolis KL, O'Connor P, Lipkin EW, Hirsch J, Coker L, Maldjian J, Sunshine JL, Truwit C, Davatzikos C, Bryan RN; ACCORD MIND investigators..

Lancet Neurol. 2011 Nov;10(11):969-77. doi: 10.1016/S1474-4422(11)70188-0. Epub 2011 Sep 28.

16.

Multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: the Microalbuminuria Education and Medication Optimisation (MEMO) study.

Crasto W, Jarvis J, Khunti K, Skinner TC, Gray LJ, Brela J, Troughton J, Daly H, Lawrence IG, McNally PG, Carey ME, Davies MJ.

Diabetes Res Clin Pract. 2011 Sep;93(3):328-36. doi: 10.1016/j.diabres.2011.05.008. Epub 2011 Jun 2.

PMID:
21640424
17.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
18.

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.

Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S; ACCORD Investigators..

BMJ. 2010 Jan 8;340:b5444. doi: 10.1136/bmj.b5444.

19.

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.

Bosi E, Dotta F, Jia Y, Goodman M.

Diabetes Obes Metab. 2009 May;11(5):506-15. doi: 10.1111/j.1463-1326.2009.01040.x. Epub 2009 Mar 23.

PMID:
19320662
20.

Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus.

Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC.

Br J Clin Pharmacol. 2009 May;67(5):547-57. doi: 10.1111/j.1365-2125.2009.03391.x. Epub 2009 Feb 11.

Supplemental Content

Support Center